Bristol-Myers Squibb Company of New York, NY, and Summit, NJ-based Celgene Corporation have announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately US$74 billion.
